A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility

ABSTRACT Candida parapsilosis has emerged as a common cause of invasive fungal infection, especially in Latin America and in the neonatal setting. C. parapsilosis is part of a closely related group of organisms that includes the species Candida orthopsilosis and Candida metapsilosis. All three species show elevated MICs for the new echinocandin class drugs caspofungin, micafungin, and anidulafungin relative to other Candida species. Despite potential impacts on therapy, the mechanism behind this reduced echinocandin susceptibility has not been determined. In this report, we investigated the role of a naturally occurring Pro-to-Ala substitution at amino acid position 660 (P660A), immediately distal to the highly conserved hot spot 1 region of Fks1p, in the reduced-echinocandin-susceptibility phenotype. Kinetic inhibition studies demonstrated that glucan synthase from the C. parapsilosis group was 1 to 2 logs less sensitive to echinocandin drugs than the reference enzyme from C. albicans. Furthermore, clinical isolates of C. albicans and C. glabrata which harbor mutations at this equivalent position also showed comparable 2-log decreases in target enzyme sensitivity, which correlated with increased MICs. These mutations also resulted in 2.4- to 18.8-fold-reduced Vmax values relative to those for the wild-type enzyme, consistent with kinetic parameters obtained for C. parapsilosis group enzymes. Finally, the importance of the P660A substitution for intrinsic resistance was confirmed by engineering an equivalent P647A mutation into Fks1p of Saccharomyces cerevisiae. The mutant glucan synthase displayed characteristic 2-log decreases in sensitivity to the echinocandin drugs. Overall, these data firmly indicate that a naturally occurring P660A substitution in Fks1p from the C. parapsilosis group accounts for the reduced susceptibility phenotype.

[1]  M. Cuenca‐Estrella,et al.  Prevalence and Susceptibility Profile of Candida metapsilosis and Candida orthopsilosis: Results from Population-Based Surveillance of Candidemia in Spain , 2008, Antimicrobial Agents and Chemotherapy.

[2]  G. Forrest,et al.  Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. , 2008, The Journal of infection.

[3]  M. Pfaller,et al.  Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis: a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 , 2008, Journal of Clinical Microbiology.

[4]  M. Pfaller,et al.  In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance , 2007, Journal of Clinical Microbiology.

[5]  B. Arthington-Skaggs,et al.  Paradoxical Growth Effect of Caspofungin Observed on Biofilms and Planktonic Cells of Five Different Candida Species , 2007, Antimicrobial Agents and Chemotherapy.

[6]  D. Perlin Resistance to echinocandin-class antifungal drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  G. Butler,et al.  Transcriptional Response of Candida parapsilosis following Exposure to Farnesol , 2007, Antimicrobial Agents and Chemotherapy.

[8]  A. Colombo,et al.  Prospective Observational Study of Candidemia in São Paulo, Brazil: Incidence Rate, Epidemiology, and Predictors of Mortality , 2007, Infection Control & Hospital Epidemiology.

[9]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[10]  M. Feldmesser,et al.  Development of Candidemia on Caspofungin Therapy: a Case Report , 2006, Infection.

[11]  M. Pfaller,et al.  Global Surveillance of In Vitro Activity of Micafungin against Candida: a Comparison with Caspofungin by CLSI-Recommended Methods , 2006, Journal of Clinical Microbiology.

[12]  J. Bennett Echinocandins for candidemia in adults without neutropenia. , 2006, The New England journal of medicine.

[13]  Benjamin J Park,et al.  Epidemiology of Candidemia in Brazil: a Nationwide Sentinel Surveillance of Candidemia in Eleven Medical Centers , 2006, Journal of Clinical Microbiology.

[14]  S. Katiyar,et al.  Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility , 2006, Antimicrobial Agents and Chemotherapy.

[15]  Sergey V. Balashov,et al.  Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1 , 2006, Antimicrobial Agents and Chemotherapy.

[16]  A. Colombo,et al.  Clinical and microbiological aspects of candidemia due to Candida parapsilosis in Brazilian tertiary care hospitals. , 2006, Medical mycology.

[17]  M. Cuenca‐Estrella,et al.  Epidemiology, Risk Factors, and Prognosis of Candida parapsilosis Bloodstream Infections: Case-Control Population-Based Surveillance Study of Patients in Barcelona, Spain, from 2002 to 2003 , 2006, Journal of Clinical Microbiology.

[18]  V. Morrison Echinocandin antifungals: review and update , 2006, Expert review of anti-infective therapy.

[19]  M. Pfaller,et al.  In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance , 2006, Journal of Clinical Microbiology.

[20]  M. Pfaller,et al.  In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole , 2005, Journal of Clinical Microbiology.

[21]  S. Katiyar,et al.  Promoter-dependent disruption of genes: simple, rapid, and specific PCR-based method with application to three different yeast , 2005, Current Genetics.

[22]  S. A. Parent,et al.  Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[23]  M. Maiden,et al.  Candida orthopsilosis and Candida metapsilosis spp. nov. To Replace Candida parapsilosis Groups II and III , 2005, Journal of Clinical Microbiology.

[24]  J. Perfect,et al.  Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species , 2004, Journal of Clinical Microbiology.

[25]  A. Safdar,et al.  The predictors of outcome in immunocompetent patients with hematogenous candidiasis. , 2004, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[26]  A. Espinel-Ingroff In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. , 2003, Revista iberoamericana de micologia.

[27]  D. Denning Echinocandin antifungal drugs , 2003, The Lancet.

[28]  N. Wiederhold,et al.  The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy , 2003, Expert opinion on investigational drugs.

[29]  T. Edlind,et al.  Histone Deacetylase Inhibitors Enhance Candida albicans Sensitivity to Azoles and Related Antifungals: Correlation with Reduction in CDR and ERG Upregulation , 2002, Antimicrobial Agents and Chemotherapy.

[30]  D. Armstrong,et al.  Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. , 2002, Diagnostic microbiology and infectious disease.

[31]  L. Saiman,et al.  Risk factors for Candida species colonization of neonatal intensive care unit patients. , 2001, The Pediatric infectious disease journal.

[32]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[33]  A. Mitchell,et al.  Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors , 1997, Antimicrobial agents and chemotherapy.

[34]  N. Morin,et al.  Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase , 1995, Molecular and cellular biology.

[35]  N. Morin,et al.  The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .